Elevation Oncology (ELEV) News Today → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free ELEV Stock Alerts $3.72 -0.01 (-0.27%) (As of 11:44 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 4:28 AM | americanbankingnews.comElevation Oncology (NASDAQ:ELEV) Now Covered by StephensMay 14 at 11:29 PM | msn.comStephens & Co. Initiates Coverage of Elevation Oncology (ELEV) with Overweight RecommendationMay 14 at 8:42 AM | marketbeat.comElevation Oncology, Inc. (NASDAQ:ELEV) Receives Average Rating of "Buy" from AnalystsElevation Oncology, Inc. (NASDAQ:ELEV - Get Free Report) has been given a consensus recommendation of "Buy" by the six research firms that are currently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price objectiMay 14 at 8:19 AM | marketbeat.comElevation Oncology (NASDAQ:ELEV) Coverage Initiated by Analysts at StephensStephens initiated coverage on shares of Elevation Oncology in a research note on Tuesday. They issued an "overweight" rating and a $8.00 target price on the stock.May 7, 2024 | prnewswire.comElevation Oncology to Present at the Citizens JMP Life Sciences ConferenceMay 4, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Elevation Oncology (ELEV), Moderna (MRNA)May 3, 2024 | marketbeat.comElevation Oncology (NASDAQ:ELEV) Given "Outperform" Rating at WedbushWedbush reissued an "outperform" rating and issued a $8.00 price target on shares of Elevation Oncology in a research note on Friday.May 2, 2024 | markets.businessinsider.comHint Health Announces 8th Annual Hint Summit, the Leading DPC Innovation ConferenceMay 2, 2024 | msn.comElevation Oncology GAAP EPS of -$0.23May 2, 2024 | marketwatch.comElevation Oncology Shares Swing to 5% Gain After Extending Cash RunwayMay 2, 2024 | msn.comELEV Stock Earnings: Elevation Oncology Misses EPS for Q1 2024May 2, 2024 | prnewswire.comElevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business AchievementsApril 26, 2024 | finance.yahoo.comClariane: First Quarter 2024 RevenueApril 22, 2024 | seekingalpha.comElevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)April 17, 2024 | marketbeat.comElevation Oncology, Inc. (NASDAQ:ELEV) Short Interest Up 8.2% in MarchElevation Oncology, Inc. (NASDAQ:ELEV - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 5,010,000 shares, a growth of 8.2% from the March 15th total of 4,630,000 shares. Currently, 12.6% of the shares of the company are sold short. Based on an average daily volume of 3,060,000 shares, the days-to-cover ratio is currently 1.6 days.April 10, 2024 | msn.comBiologic drug-device combination immunotherapy for metastatic prostate cancer patientsApril 9, 2024 | markets.businessinsider.comPromising Preclinical Data and Positive Phase 2 Results Bolster Buy Rating for Elevation OncologyApril 9, 2024 | marketbeat.comElevation Oncology (NASDAQ:ELEV) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $6.00 price target on shares of Elevation Oncology in a research report on Tuesday.April 8, 2024 | finance.yahoo.comElevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024March 30, 2024 | marketbeat.comShort Interest in Elevation Oncology, Inc. (NASDAQ:ELEV) Expands By 28.3%Elevation Oncology, Inc. (NASDAQ:ELEV - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 4,630,000 shares, a growth of 28.3% from the February 29th total of 3,610,000 shares. Based on an average daily volume of 2,940,000 shares, the days-to-cover ratio is currently 1.6 days. Approximately 11.6% of the company's stock are short sold.March 28, 2024 | msn.comDesign for proposed southern Utah reservoir is poor and poses risk to public safety, geophysicist saysMarch 28, 2024 | msn.comMelanoma: All about the risks, symptoms, and common mythsMarch 27, 2024 | msn.comUp 825% So Far in 2024, Can This Penny Stock Go Any Higher?March 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)March 9, 2024 | benzinga.comElevation Oncology Stock (NASDAQ:ELEV), Quotes and News SummaryMarch 8, 2024 | investorplace.comAll Three of Our Analysts AgreeMarch 8, 2024 | marketbeat.comElevation Oncology, Inc. to Post Q4 2025 Earnings of ($0.16) Per Share, HC Wainwright Forecasts (NASDAQ:ELEV)Elevation Oncology, Inc. (NASDAQ:ELEV - Free Report) - Equities research analysts at HC Wainwright issued their Q4 2025 EPS estimates for shares of Elevation Oncology in a note issued to investors on Thursday, March 7th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnMarch 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Elevation Oncology (ELEV) and OrthoPediatrics (KIDS)March 7, 2024 | finance.yahoo.comElevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023March 7, 2024 | marketbeat.comElevation Oncology (NASDAQ:ELEV) Stock Rating Reaffirmed by JMP SecuritiesJMP Securities reiterated a "market outperform" rating and set a $7.00 price target on shares of Elevation Oncology in a research report on Thursday.March 6, 2024 | markets.businessinsider.comElevation Oncology, Inc. Q4 Loss decreases, beats estimatesMarch 6, 2024 | msn.comELEV Stock Earnings: Elevation Oncology Beats EPS for Q4 2023March 6, 2024 | finance.yahoo.comElevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024March 6, 2024 | finance.yahoo.comElevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business AchievementsMarch 5, 2024 | investorplace.comTrim the Fat: 3 Overbought Stocks Poised for a PullbackMarch 4, 2024 | marketbeat.comElevation Oncology, Inc. (NASDAQ:ELEV) Shares Sold by Armistice Capital LLCArmistice Capital LLC lowered its stake in shares of Elevation Oncology, Inc. (NASDAQ:ELEV - Free Report) by 68.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 750,000 shares of the company's stockMarch 4, 2024 | finance.yahoo.comElevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of DirectorsMarch 4, 2024 | marketbeat.comElevation Oncology, Inc. (NASDAQ:ELEV) Sees Large Growth in Short InterestElevation Oncology, Inc. (NASDAQ:ELEV - Get Free Report) was the target of a large increase in short interest in February. As of February 15th, there was short interest totalling 4,010,000 shares, an increase of 13.9% from the January 31st total of 3,520,000 shares. Based on an average daily trading volume, of 2,620,000 shares, the short-interest ratio is presently 1.5 days. Approximately 11.6% of the shares of the stock are short sold.March 2, 2024 | msn.comJMP Securities Initiates Coverage of Elevation Oncology (ELEV) with Market Outperform RecommendationMarch 1, 2024 | markets.businessinsider.comOptimistic Buy Rating for Elevation Oncology on EO-3021’s Promising Clinical Advancements and DifferentiationMarch 1, 2024 | marketbeat.comElevation Oncology (NASDAQ:ELEV) Coverage Initiated by Analysts at JMP SecuritiesJMP Securities began coverage on shares of Elevation Oncology in a research report on Friday. They set an "outperform" rating and a $7.00 price objective on the stock.February 29, 2024 | prnewswire.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the FirmFebruary 28, 2024 | finance.yahoo.comElevation Oncology to Participate in Upcoming Investor ConferencesFebruary 28, 2024 | prnewswire.comElevation Oncology to Participate in Upcoming Investor ConferencesFebruary 24, 2024 | msn.comElevation Oncology expands Phase I solid tumour trial to JapanFebruary 24, 2024 | msn.comElevation Oncology (ELEV) Price Target Increased by 31.03% to 6.46February 23, 2024 | investorplace.com3 Stock Winners That Are Up 400% or More in 2024February 22, 2024 | finance.yahoo.comElevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in JapanFebruary 22, 2024 | prnewswire.comElevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in JapanFebruary 22, 2024 | marketbeat.comElevation Oncology, Inc. (NASDAQ:ELEV) to Post Q1 2024 Earnings of ($0.28) Per Share, HC Wainwright ForecastsElevation Oncology, Inc. (NASDAQ:ELEV - Free Report) - Analysts at HC Wainwright cut their Q1 2024 earnings per share estimates for Elevation Oncology in a research note issued on Tuesday, February 20th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share Get Elevation Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter. Email Address Tiny AI projects with huge promise hiding in plain sight … (Ad)I’ve developed a system that’s helped me find huge winners in the past. Now my system has alerted me to the next four altcoins that could be the next superstars. Click here to find out who they are. ELEV Media Mentions By Week ELEV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELEV News Sentiment▼0.630.55▲Average Medical News Sentiment ELEV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELEV Articles This Week▼61▲ELEV Articles Average Week Get Elevation Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: FENC News KOD News ADVM News IPSC News GNFT News INMB News CGEN News OPT News IPHA News CLLS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELEV) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTop 5 AI Stocks to Buy for 2024Market Moving TrendsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCharles Payne Demystifies OptionsUnstoppable ProsperityTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
